PROMIS NEUROSCIENCES EXCEEDS TARGET ENROLLMENT IN PRECISE-AD PHASE 1B CLINICAL TRIAL OF PMN310 IN ALZHEIMER’S DISEASE

Reuters · 2d ago

Please log in to view news